D (more than 6 months) 江角　真理子 Mariko ESUMI HCV Tg/#FS2-5 HCV Tg/#FS2-5 In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. 後日指定The RECIPIENT must consult with the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。後日指定<br>利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。寄託者（開発者）の承諾を得る。 pcD-SRa-derived expression vector, pME18S, which is composed of the simian virus 40 (SV40) ori, SV40 early promoter and a part of the long terminal repeat of human T-cell leukemia virus type 1, HCV cDNA (全長翻訳遺伝子, 3’ Xを欠) (human), SV40 polyA signal D（6か月以上） Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> RBRC03578 true